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Abstract
Therapies for blood genetic diseases can be divided into different categories, including
chemotherapy, radiotherapy, gene therapy, and hematopoietic stem cell transplantation.
Among these treatments, gene targeting is progressively becoming a therapeutic alterna‐
tive that offers the possibility of a permanent cure for certain blood genetic diseases. In
recent years, gene therapy has played a more important role in curing genetic blood dis‐
orders. RNA interference (RNAi) is one of the directions for gene therapy, which was in‐
tensively studied in the past decades for its potentials in the treatment of diseases. In
order to provide useful references and prospective directions for further studies concern‐
ing RNAi-based gene therapy for blood genetic diseases, current RNAi-based gene thera‐
pies for several typical blood genetic diseases have been summarized and discussed in
this chapter.
Keywords: RNA interference, gene therapy, mechanism, therapeutic strategy, blood ge‐
netic diseases
1. Introduction
Conceived in the 1960s, gene therapy did not produce any meaningful results until recent
reports of success appeared in clinical studies. Gene therapy attempts to treat inherited
diseases using normal copies of the defective genes. Insertion and expression of specific
exogenous genetic materials via the transfer of nucleic acids directly in vivo, or through
modified cells in vitro, correct a cellular dysfunction or provide a new cellular function. It has
the potential to cure any genetic disease with long-lasting therapeutic benefits [1, 2]. Gene
therapy can be classified into (i) germ line and (ii) somatic line gene therapy types. In the
former, genomes of germ cells (sperms or eggs) are integrated by exogenous functional genes,
which can be carried onto the patient’s offsprings. In the latter, therapeutic genes are intro‐
duced into somatic cells and the effects will only be limited to the individual patient [3].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
According to the mechanisms, gene therapy may include three major categories: (a) direct
modulation of the disease-causing gene, which can be applied to monogenic hereditary
diseases; (b) indirect treatment through gene modulation, which can be applied to multifac‐
torial diseases; and (c) immunotherapy by gene modulation (DNA vaccines), which leads to
the synthesis of the relevant antigen or an adjuvant [1].
RNA interference (RNAi) can be used for gene therapy. It was intensively studied in the past
few decades for its potential in the treatment of blood genetic diseases. RNAi-based gene
therapy possesses several therapeutic advantages such as high efficiency, sequence specificity,
and potentially less immunogenicity. Less immunogenicity is largely due to the use of non-
protein-coding “gene products” to trigger RNAi, which makes gene therapy less likely to be
potentially hampered by the host immune system [4, 5]. Compared to traditional small
molecules and protein drugs, the target specificity and universal treatment spectrum make
RNAi-based gene therapy an ideal treatment for blood genetic diseases. However, there are
still obstacles that remain, such as barriers in the blood circulation system and the diseased
tissues that block the actualization of the RNAi effects [6]. RNAi technology is a relatively new
discovery, and it has already become a potent method for gene regulation. In order to provide
useful references and prospective directions for further studies, current RNAi-based gene
therapies for blood genetic diseases have been summarized and discussed in this chapter.
2. The mechanism of RNAi-based gene therapy
Being a well-described gene regulatory mechanism, RNAi not only suppresses transcription
by transcriptional gene silencing (TGS) but also activates a homology-based mRNA degrada‐
tion process by post-transcriptional gene silencing (PTGS). Both silencing pathways resulted
in the decrease of the coding transcript level (mRNA) [7]. We will focus on PTGS due to its
important role in RNAi-based gene therapy. Two distinct mechanisms regulate PTGS. The first
one is the repression and degradation of mRNAs with imperfect complementarity. Endoge‐
nous microRNAs (miRNAs) belong to this category. They induce translational repression and
mRNA degradation when the guide (antisense) strand has limited complementarity to the
target mRNA. The second one is the sequence-specific cleavage of perfectly complementary
mRNAs. Exogenous small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) belong
to this category. They have perfect or near-perfect base-pairings with the intended target
mRNA. The miRNAs production and processing rely on host machinery that is guided by
complementary miRNA strands to the target mRNA [8, 9]. During the process, double-
stranded RNAs (dsRNA) of the target gene are produced and then processed into 21–24 non-
coding small RNA duplexes with the help of RNaseIII enzyme dicer and its homologs. These
siRNAs are then incorporated into a multi-subunit endonuclease silencing complex called
RNA-induced silencing complex (RISC). siRNAs are associated with the defense against
parasites, heterochromatin formation, transposon and transgene silencing, and PTGS. These
siRNAs, loaded into the RISC, are used as the guide to recognize and degrade or suppress the
complementary gene or mRNA utilizing the endonucleases activity of RISC. Gene silencing
by RNAi can be used in different biological situations when sequence-specific knockdown of
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gene expression is required, thus providing a convenient tool for analysis of gene function as
well as gene therapy [10, 11, 12].
Recent reports have shown that off-targeting can commonly occur during RNAi, despite the
belief that initial gene silencing through RNAi was thought to be specific. Because nonspecific
hybridization of siRNAs with non-target transcripts can induce undesired effects, it should be
guaranteed that the dsRNA and corresponding siRNA sequences do not exert off-target effects
that negatively influence host physiology. Off-target silencing is determined by the similarity
of sequences between siRNA and non-target genes, or mRNA sequences not selected for RNAi,
as well as the size of siRNA and transitive RNAi. Thus, off-targeting effects can be avoided by
using highly specific sequences in siRNA expressed under specific and inducible promoters.
In addition, it is important to examine the off-targeting effects of RNAi at multiple levels, since
undesired effects on the host may occur through the silencing of genes associated with
regulatory functions and multiple metabolic pathways, such as transcription factors or
signaling molecules [10].
3. RNAi-based gene therapy for blood genetic diseases
3.1. Blood diseases
Blood diseases refer to the disorders in the hematopoietic system or plasma components. The
development of blood disorders is always thought to be related with inheritance, the envi‐
ronment, drugs, and biological factors where the changes in chromosome and/or genes play
a critical role in some specific hemopathies. Therapeutic approaches for blood diseases can be
divided into different categories, including chemotherapy, radiotherapy, RNAi-based gene
therapy, and hematopoietic stem cell transplantation. Among these, RNAi-based gene therapy
is progressively becoming a therapeutic alternative which offers the possibility of a permanent
cure for some blood diseases [13].
3.2. Hemophilia
Hemophilia A and B are X-linked monogenic bleeding disorders resulting from deficiencies
of factor VIII and IX, respectively. Gene therapy, utilizing both viral and non-viral delivery
vectors in vivo and ex vivo, has been attempted for the treatment of both hemophilia A and B
[14, 15]. Given its recent clinical success, adeno-associated vector (AAV)-mediated hepatic
gene transfer could be primarily used for the treatment of hemophilia B. However, a number
of problems, such as current immunosuppressive regimen and pre-existing neutralizing
antibodies, limit the broad applicability of this approach. For hemophilia A, while AAV-
mediated gene therapy has potential, a number of limitations reduce its desirability, such as
packaging capacity and inefficient expression. While a number of transgene modifications
have increased the expression levels, the vector doses require the corrective F.VIII expression
to remain significantly higher than the F.IX. These expression limitations lead to further
concerns about immune responses to both the capsid and, if expression levels are not sufficient,
the transgene. As such, ex vivo gene transfer may be more effective for hemophilia A due to its
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ability to enhance expression through cellular division. While a number of promising gene
therapies for hemophilia have been elucidated, there are clearly numerous problems that still
need to be addressed to develop approved gene therapies, especially RNAi, for both hemo‐
philia A and B in humans [16]. RNAi-based gene therapy for hemophilia is still in its early
stages of development.
3.3. β-Thalassemia
The globin chains have an extremely precise structure, ensuring their function of loading,
delivering, and unloading oxygen. The globin chains are coded by genes in the chromosome
16 (α-gene) and 11(β-gene). The normal structure of globin is based on the balanced match
between α-chains and β-chains. When the condition is not met, there will be a complete or
partial defect in one or both allelic globin genes, such as β-thalassemia [17]. β-Thalassemia is
a worldwide-distributed inherited hemoglobin disorder resulting in severe, chronic anemia
[18, 19]. It is a heterozygous condition in which only a single β-globin gene is affected and
results in the absence or reduced β-globin chain synthesis. The defects of β-globin synthesis
lead to an excess of unmatched α-globin, which release free iron, non-heme iron, or hemi‐
chrome. These iron species promote a severe red cell membrane oxidative stress and lead to
abnormal β-thalassemic red cell features. The abnormal red cells are finally removed by the
macrophage system and results in anemia [20, 21].
Blood transfusion is a primary way to treat the most severe forms of β-thalassemia. Appro‐
priate goals and optimal safety of transfused blood are necessary for routine administration
of red blood cells to patients. The problem is that the high frequency of blood transfusion can
lead to iron overload. In its less severe form, chronic transfusions are not required, but iron
overload may still develop due to the chronic suppression of the synthesis of the iron regula‐
tory hormone hepcidin by ineffective erythropoiesis. Untreated iron overload can be fatal,
resulting in cardiac complications [3, 22]. Therefore, handling iron overload is a key factor for
the successful treatment of this disease. TMPRSS6, a serine protease expressed predominantly
in the liver, can inhibit an iron-responsive bone morphogenetic protein-mother against the
decapentaplegic (BMP-SMAD) signaling pathway, resulting in the downregulation of
hepcidin transcription. Researchers found that therapeutics with the lipid nanoparticle (LNP)-
formulated RNAi targeting of TMPRSS6, in conjunction with oral deferiprone therapy, is
superior to monotherapy with dietary iron deficiency and iron chelate for reducing hepatic
iron storage [22].
3.4. B-lineage lymphoid malignancies
B-precursor acute lymphoblastic leukemia (BPL) is the most common form of cancer in
children and adolescents. A dysfunctional CD22 is expressed in BPL cells due to the deletion
of Exon 12 (CD22ΔE12) resulting from a splicing defect related to homozygous intronic
mutations. CD22 is a negative regulator of multiple signal transduction pathways critical for
the proliferation and survival of B-lineage lymphoid cells, and CD22ΔE12 leads to uncontrol‐
led proliferation and the survival of B cells. Recently, researchers have found that CD22ΔE12
is especially associated with therapy-refractory clones in pediatric BPL, thus implicating the
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impact of the CD22ΔE12 genetic defect on the aggressive biology of relapsed or therapy-
refractory pediatric BPL. At the same time, forced expression of CD22ΔE12 in transgenic mice
causes fatal BPL, demonstrating that CD22ΔE12 alone is sufficient as an oncogenic driver lesion
for malignant transformation and clonal expansion of B-cell precursors [23].
Recent studies have demonstrated that B-lineage lymphoid malignancies in children and
adults are characterized by a high incidence of the CD22ΔE12 genetic alterations. Moreover,
the relationship between CD22ΔE12 and aggressive biology of BPL cells is also reported
through the demonstration that siRNA-mediated knockdown of CD22ΔE12 in primary BPL
cells is associated with a remarkable inhibition of their carcinogenicity. A unique polypeptide-
based nanoparticle formulation of CD22ΔE12-siRNA is described as a first-in-class RNAi
therapeutic candidate targeting of CD22ΔE12. This formulation is capable of delivering siRNA
cargo into the cytoplasm of leukemia cells, leading to a remarkable inhibition of leukemic cell
growth [24]. It is expected that further development of this nanoparticle may promote an
effective therapeutic RNAi strategy of aggressive or chemotherapy-resistant B-lineage
lymphoid malignancies [23].
3.5. Myeloid leukemia
Leukemia arising from genetic alterations in normal hematopoietic stem or progenitor cells
results in the impaired regulation of proliferation, differentiation, and apoptosis, as well as the
survival of malignant cells. Overall, the relative 5-year survival rate for various leukemias is
only around 50% [25]. Leukemia is still a worldwide health problem, although various
therapies have been explored to cure the disease. Among them, chemotherapy is always
considered to be a frontline treatment, mainly containing a broad spectrum of cytotoxic agents
and therapeutic molecules. Although leukemic cells respond well to chemotherapy at the onset
of treatment, over a period of 6–12 months the drugs might lose effectiveness in a considerable
fraction of patients. Moreover, significant side effects of traditional cytotoxic agents are
inevitable at efficacious doses, which limit its function with the progression of the disease. For
example, in chronic myeloid leukemia (CML), resistance to current frontline therapy of
imatinib and failure to a complete cytogenetic response may occur in 24% of patients within
18 months. With a better understanding of molecular changes in leukemia, the treatment
targeting tumor-specific changes, such as RNAi, is expected to make a difference in the
therapeutic effectiveness of the disease [26].
Researchers have explored the suitability of RNAi in suppressing the growth and proliferation
of myeloid leukemia cell lines including HL-60, U937, THP-1, and K562, which express c-raf
and bcl-2 genes. The results were exciting, as the siRNA duplexes succeeded in significantly
decreasing the level of target proteins by eliminating the expression of c-raf and bcl-2 genes.
This led to the inhibition of the differentiation and programmed cell death suppression of
myeloid leukemia cells. These results demonstrated the possibility of RNAi as a novel
therapeutic approach to myeloid leukemia [27]. In recent years, based on the molecular
alteration of CML, two clinical trials of RNAi therapy have been conducted to target the
aberrantly expressed isoforms of the BCR-ABL fusion protein. In one case, there are no
publishable outcomes. In the other case, silencing aberrant proteins with RNAi have been
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found to be less prone to drug resistance [28]. In another in vivo application of targeted and
non-virally delivered synthetic bcr-abl siRNA, a remarkable apoptosis of CML cells was found
in a female patient with a recurrent Philadelphia chromosome with positive CML. The patient
was resistant to imatinib and chemotherapy after hematopoietic stem cell transplantation.
There were no clinically adverse events, implying feasibility and safety of the application of
RNAi-based gene therapy for CML [29].
Furthermore, RNAi-based gene therapy also proves to be effective in acute promyelocytic
leukemia (APL). APL is the M3 type of acute myeloid leukemia characterized by a clonal
proliferation of abnormal promyelocytes in bone marrow and has a severe bleeding tendency.
In 98% of APL patients, a balanced translocation between chromosomes 15 and 17 [t(15;17)
(q22;q21)] was found, which leads to the formation and fusion of promelocytic leukemia
protein (PML) and retinoic acid receptor alpha (RARα) [30, 31]. A variety of chromosomal
aberrations have been identified in APL including t(11;17)(q23;q21), t(5;17)(q35;q12-21),
t(11;17)(q13;q21), and der(17), in which the RARα gene is fused to the PLZF, NPM, NuMA,
and STAT5b genes, respectively [32]. The differentiation of leukemic cells and complete
remission of APL may occur after treatment with ATRA (all-trans retinoic acid). However, the
alternative strategies of specific targeting of APL are required because of the ATRA resistance
in patients with PLZF-RARα fusion mutation and a treatment of relapse. It has been found
that the siRNA targeted knockdown of fused PML-RARα mRNA can induce differentiation
and apoptosis of human APL cells; moreover, an injection of pretreated APL cells with anti-
PML-RARα siRNA greatly inhibits the progression of APL in mice. Therefore, a targeted RNAi
for PML-RARα fusion might be a promising treatment strategy for ATRA-resistant APL
patients [33].
At present, several technological requirements and mechanistic challenges (i.e., targeted
delivery of siRNAs) for efficient clinical trials have to be explored and overcome to make RNAi-
based gene therapy readily applicable for the treatment of myeloid leukemia [26].
3.6. Multiple myeloma
Multiple myeloma (MM) of clonal plasma cells in bone marrow can cause damage to multiple
organs. MM is the second most common hematological malignancy. Chromosomal abnor‐
malities, oncogene activation, and growth factor dysregulation contribute to the development
of MM. Like leukemia, chemotherapy is the most common treatment for MM right now.
However, it is remarkably resistant to chemotherapy [34]. Molecular therapy became an
alternative treatment, and the introduction of bortezomib has contributed to the improved
survival of patients with MM. Resistance to this therapy inevitably occurs, and the clinical
efficacy of bortezomib is significantly diminished. At present, RNAi is found to be helpful in
sensitizing tumor cells to chemotherapy and radiation. Bmi-1, an oncogene, has been impli‐
cated in the pathogenesis of MM and might influence the response to bortezomib in MM
patients. Bmi-1 has been silenced in two MM cell lines using shRNA targeting Bmi-1 (shBmi-1).
The cell cycle progression and apoptosis of MM cells are evaluated. The prolonged G1 phase
and enhanced apoptosis were observed that suggest RNAi-derived knockdown of Bmi-1
reducing the resistance to bortezomib. Therefore, Bmi-1-specific RNAi may serve as an
important treatment strategy for MM [35].
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4. Conclusions and future perspectives
As a powerful and novel treatment of blood genetic diseases, RNAi-based gene therapy has
propelled the clinical testing of siRNAs for a variety of diseases at early stages. It is still too
early to determine whether the RNAi-based therapeutics will be an efficient tool for the
treatment of blood genetic diseases. Therefore, understanding the basic mechanisms of a
targeted gene RNAi and its interconnection with genetic, biochemical, and physiological
pathways, as well as “off-targets” and “side effects,” are the most important factor for
developing an efficient therapeutic RNAi strategy. It is highly possible that the RNAi-based
gene therapy can be readily and efficiently used for clinical treatment in conjunction with other
therapies. The power of sequence-specific suppression of gene expression without “off-
targets” and undesired side effects makes RNAi-based gene therapy very promising. Although
progress has been made [36], major obstacles, such as the development of methods for efficient
targeted delivery of siRNAs in patients, still remain a critical task. In addition, uncovering
target domains of genes related to blood genetic diseases and the discovery of more blood
genetic disease-causing genes are also key research areas for developing RNAi-based gene
therapy for important blood genetic diseases.
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